FDA Grants Breakthrough Therapy Designation to Adrabetadex for Infantile-Onset Niemann-Pick Disease Type C
核心洞察
The FDA has granted Breakthrough Therapy Designation to adrabetadex for infantile-onset Niemann-Pick disease type C (搜索), based on survival analyses showing improved outcomes compared to external controls.
Adrabetadex directly addresses the underlying pathology of NPC (搜索) by re-establishing intracellular cholesterol trafficking, marking a potential therapeutic breakthrough for this devastating neurodegenerative disorder.
Beren Therapeutics plans to submit a New Drug Application in the near future, with the drug expected to be eligible for Priority Review given its orphan drug status.
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to adrabetadex, an investigational cyclodextrin-based drug for infantile-onset Niemann-Pick disease type C (搜索) (NPC (搜索)), marking a significant regulatory milestone for patients facing this devastating neurodegenerative disorder. Beren Therapeutics P.B.C. (搜索), through its subsidiary Mandos LLC, announced the designation on December 9, 2025, following FDA review of survival analyses demonstrating improved outcomes in adrabetadex-treated patients compared to external controls.
Regulatory Pathway and Clinical Evidence
The FDA's decision to grant Breakthrough Therapy Designation was informed by an externally controlled survival analysis showing that adrabetadex improves survival in individuals with infantile-onset NPC (搜索). The designation, which expedites development of drugs for serious or life-threatening conditions, was supported by biomarker and nonclinical data alongside the survival analysis.
"This newly granted designation represents an important milestone in the evaluation of adrabetadex for people living with infantile-onset NPC (搜索)," said Jason Camm, Chief Executive Officer of Beren Therapeutics P.B.C. (搜索) "We are grateful to the people living with NPC and their caregivers, clinicians, and advocates who have worked with us through a long development path."
The drug's development history includes a previous Breakthrough Therapy Designation granted in 2016 under a prior sponsor, which the FDA later rescinded based on data from a 12-month Phase 2b/3 clinical trial. Beren acquired the adrabetadex program from Mallinckrodt in 2021 and has since worked closely with the FDA and NPC (搜索) community to generate the data supporting the new designation.
Disease Background and Unmet Medical Need
Niemann-Pick disease type C (搜索) is a rare, autosomal-recessive, severe neurodegenerative disorder caused by pathologic variants in the NPC1 (搜索) gene (approximately 95% of cases) or NPC2 (搜索) genes. The genetic defects lead to impaired cholesterol trafficking, resulting in progressive neurological decline and premature death.
Infantile-onset NPC (搜索) refers to cases where individuals first experience neurological symptoms between 0 and 6 years of age. The disease demonstrates a clear correlation between earlier onset and worse prognosis, with mean survival of approximately 5.6 years for early-infantile-onset (neurological onset before age 2) and approximately 13.4 years for late-infantile-onset (onset between 2 and 6 years). Patients typically present with manifestations affecting multiple organs, with the most severe and debilitating effects occurring in the brain.
Dr. Elizabeth Berry-Kravis, Professor of Pediatrics at Rush University Medical Center and principal Expanded Access Program investigator, emphasized the clinical significance: "Infantile-onset NPC (搜索) is a devastating, rapidly fatal diagnosis. Seeing statistically significant improvements in survival signals a meaningful shift in what is achievable for these patients."
Mechanism of Action and Safety Profile
Adrabetadex (VTS-270) is a proprietary mixture of 2-hydroxypropyl-β-cyclodextrin (搜索) isomers that directly addresses the underlying pathology of NPC (搜索) by re-establishing intracellular cholesterol trafficking. This mechanism targets the fundamental defect causing the disease rather than merely managing symptoms.
The drug is generally well tolerated, with the main adverse events including hearing impairment that can be managed with hearing aids when necessary, and post-dose fatigue and/or ataxia. Beren and Mandos have supported the NPC (搜索) community by providing access to adrabetadex through an Expanded Access Program.
Regulatory Status and Future Plans
Adrabetadex holds multiple regulatory designations including Orphan Drug and Rare Pediatric Disease designations in addition to the newly granted Breakthrough Therapy Designation. Beren plans to submit a New Drug Application in the near future and expects adrabetadex to be eligible for Priority Review.
The company, headquartered in Thousand Oaks, California, is a founder-led, clinical-stage biotechnology company pioneering cyclodextrin-based therapeutics for conditions characterized by defective cholesterol trafficking. Beren will launch its website out of stealth mode in Q1 2026, while continuing to operate through its public-facing subsidiary Mandos.
The breakthrough designation represents a critical step forward for families affected by this rare disease, potentially offering the first targeted therapy to meaningfully impact survival outcomes in infantile-onset NPC (搜索).